



The world's leader in fighting ovarian cancer



OCRA
ovarian cancer
research alliance





THANK YOU FROM OUR PRESIDENT

Dear friends,

As we look back on all that we accomplished in 2019, we are reminded of just how important this work is, and how grateful we are for you, our supporters.

So much of what we accomplished this year was due to your generosity. We are propelled by everything we have learned, and continue to learn, from the ovarian cancer community—those touched by the disease and those searching for answers. And we remain steadfast to our mission: to cure ovarian cancer, advocate for patients and support survivors and their families.

OCRA is the largest non-government funder of ovarian cancer research and has invested more than \$100 million in crucial research. OCRA fights ovarian cancer on all fronts, including in the lab and on Capitol Hill, and through innovative programs to support survivors and their families.

We are pleased to share these highlights with you, which are just a brief overview of the breadth of our work. We invite you to visit our website (ocrahope.org) or follow us on social media (@ocrahope) to stay up to date on all the latest we have to share.

On behalf of everyone at OCRA, thank you!

Sincerely,

A handwritten signature in cursive script that reads "Audra L. Moran".

Audra Moran
President & CEO

RESEARCH

PARTNERING WITH SCIENTISTS TO ERADICATE OVARIAN CANCER



OCRA is the largest non-government funder of ovarian cancer research and has the longest track record of impact. We have invested more than \$100M to jumpstart promising research and hasten desperately needed breakthroughs. Every day, OCRA-funded researchers are finding new ways to treat, prevent and, ultimately, cure ovarian cancer.



In 2019, we funded 23 investigators, awarding over \$5 million in grants.

2019 OCRA GRANTEES:

In 2019, OCRA-funded researchers made many discoveries that advanced the field of ovarian cancer research. They found that stem-like cells may be key to preventing recurrence; worked to increase efficacy of PARP inhibitors; identified genes associated with increased risk of ovarian cancer; revealed new drug therapy combinations; and investigated new approaches to using immune therapy to combat ovarian cancer.

COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Ronald Buckanovich, MD, PhD

Magee-Womens Research Institute

Targeting Tumor Desmoplasia to Enhance Immunotherapy

Rugang Zhang, PhD

The Wistar Institute

Developing Epigenetic Therapies for Ovarian Cancer

LIZ TILBERIS EARLY CAREER AWARD

Min Soon Cho, PhD

MD Anderson Cancer Center

The Role of Platelet in the Regulation of Immune Response to Ovarian Cancer

Zihua Gong, MD, PhD

Cleveland Clinic

DNA Repair Pathways as Targets for Therapy-Resistant Ovarian Cancer

Xiaowen Hu, PhD

University of Pennsylvania

Targeting Chromatin Remodeling Complex to Treat Ovarian Cancer

Kate Lawrenson, PhD

Cedars-Sinai Medical Center

Elucidating the Role of SOX17 in HGSOC

Elizabeth Stover, MD, PhD

Dana Farber Cancer Institute

Targeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian Cancer

Takemasa Tsuji, PhD

Roswell Park Comprehensive Cancer Center

Utilization of Tumor-recognizing CD4+T Cells in Cancer Immunotherapy

Kris Wood, PhD

Duke University

Precision Targeting of Altered Mitochondrial States in Ovarian Cancer

ANN AND SOL SCHREIBER MENTORED INVESTIGATOR AWARD

Kristin G. Anderson, PhD

Fred Hutchinson Cancer Research Center

Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer

Alexander Cole, PhD

Magee-Womens Research Institute

Investigating Regulators of Quiescence in Epithelial Ovarian Cancer

Sarah Gitto, PhD

University of Pennsylvania

Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer

Guy Katz, MD, PhD

MD Anderson Cancer Center

Therapeutic miRNA Targeting for Ovarian Cancer

Isaac Klein, MD, PhD

Dana Farber Cancer Institute

Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer

John Kraus, PhD

Fox Chase Cancer Center

Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer

Marilyne Labrie, PhD

Oregon Health and Science University

Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer

Jing Li, MD, PhD

University of Michigan

ARID1A Drives Ovarian Cancer Immunotherapy

Shariska Petersen, MD

University of Kansas Medical Center Research Institute

Cyclin E and BRD4 as Markers for a New PARPi Drug Combination

Alba Rodriguez-Garcia, PhD

University of Pennsylvania

Targeting MISIR with CAR T Cells for the Treatment of Ovarian Cancer

Elaine Stur, PhD

MD Anderson Cancer Center

Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer

Shuai Wu, PhD

The Wistar Institute

Synthetic Lethality for ARID1A Mutation in Ovarian Cancer

Haineng Xu, PhD

University of Pennsylvania

A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers

Zvi Yaari, PhD

Memorial Sloan Kettering Cancer Center

Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer

ADVOCACY


ENGAGING WITH POLICYMAKERS TO KEEP THIS FIGHT A PRIORITY



We are *the* voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education, patient safety, and access to high-quality care are protected on Capitol Hill. We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students program.

In 2019, 86 ovarian cancer advocates from 37 states gathered in Washington, DC to meet with their elected officials and ask them to sign onto an effort to dramatically increase funding for the Ovarian Cancer Research at the Department of Defense.

Our Advocate Leaders program grew from 36 members to 50 members representing 35 states and the District of Columbia. We helped craft legislation to reauthorize Johanna's Law, the Gynecologic Cancer Education and Awareness Act that, once enacted, will allow the program to expand and reach more people across the country. Our targeted legislative campaigns helped influence the federal government to spend a record amount of funds in support of ovarian cancer research and awareness programs.



In 2019, 86 advocates from 37 states fought to increase funding for ovarian cancer research.



Survivors Teaching Students reached nearly 13,000 medical professionals in 2019.

Survivors Teaching Students trained 142 volunteers who joined forces with a total of 998 committed individuals who shared their stories of diagnosis and treatment with 12,994 rising medical professionals at 327 schools and institutions around the U.S.

PATIENT SUPPORT

STANDING TOGETHER WITH EVERY
PERSON TOUCHED BY THE DISEASE



Our programs help people navigate an overwhelming diagnosis, supporting patients and their families when and where they need it the most. Our Woman to Woman peer support program pairs newly diagnosed patients with survivors who provide hope and insight, and our Ovarian Cancer National Conference brings survivors together to share knowledge and build community.

In 2019, OCRA brought in an oncology social worker who, in one year, fielded calls from 419 patients and trained 13 Woman to Woman mentors. Furthermore, OCRA awarded two grants for new Woman to Woman program sites, bringing the total number of sites funded to 43. Our oncology social worker also oversaw the growth of our Inspire Online Community, which boasted 54,757 members.

Our Ovarian Cancer National Conference was held in Seattle, and welcomed nearly 400 attendees from across the U.S.—and as far away as Australia!—who came together to delve into an array of topics and build community.

FUNDRAISING

BUILDING A COMMUNITY OF THOSE COMMITTED TO A CURE

A variety of events were held across the U.S. with a singular purpose: raise vital funds to support ovarian cancer research. Ranging from fitness to fashion, comedy to culinary, these events—produced by OCRA and by third parties—raised more than \$1.5 million.

STAND UP FOR MADELINE ▶ May 20, 2019

A hilarious evening for a serious cause, celebrating the life of legendary funny lady, Madeline Kahn with New York City's top comedians at Carolines on Broadway.



▲ Comedian Chris Redd



◀ HOPE FASHION SHOW Dallas, TX, September 19, 2019

OCRA's first Hope Fashion Show, sponsored by Stanley Korshak, brought together local celebrities and fashion lovers to raise awareness, money and, just as importantly, hope.



Barbara Gallagher on Mt. Elbrus in Russia, August 2019

◀ OCRA HEROES

Whether it's a lemonade stand or dance-a-thon, anyone can be a hero. OCRA heroes are everyday people doing extraordinary things like Barbara Gallagher, who climbed mountains (literally and figuratively) to reach new heights while raising awareness for ovarian cancer research.

OVARIAN CYCLE ▶

OCRA's series of indoor cycling events are the perfect way to work out, have fun and raise money for ovarian cancer research! Rides were held across the country, from San Mateo to Detroit, LA to Tampa, and everywhere in between.



Nashville, TN
December 7, 2019



▲ Elle Simone, Audra Moran, and the 2019 CHEF ON FIRE Seng Luangrath of THIP KHAO

◀ TURN UP THE HEAT DC March 5, 2019

OCRA's signature foodie event, hosted by Elle Simone of *America's Test Kitchen*, featured a private VIP reception sponsored by United Airlines and culinary delights from Washington, DC's top women chefs and mixologists.

TURN UP THE HEAT BOSTON ▶

Tuesday, April 30, 2019

Guests enjoy an evening of drinks and bites from Boston's top female chefs and mixologists at Catalyst Restaurant in Cambridge.



Photo: Lauren Killian

▼ Vivica A. Fox shops the celebrity auction before the bidding starts



Photo: Astrid Stawiarz

▲ L-R: Kate Mara, Audra Moran, President and CEO, OCRA, and host Maggie Gyllenhaal



Photo: Cindy Ord

STYLE LAB

November 6, 2019

A dazzling evening hosted by Maggie Gyllenhaal and Kate Mara, and sponsored by *InStyle* magazine, featured a live musical performance from En Vogue, fashion from top designers, exclusive personalized Style Lab experiences and a one-of-a-kind celebrity auction... all to support research and a cure for ovarian cancer.



Photo: Cindy Ord

▲ En Vogue performed live and what a performance it was!

BOARD OF DIRECTORS / NATIONAL LEADERSHIP COUNCIL

EXECUTIVE COMMITTEE

John W. Hansbury, Esq., Chair

Robin S. Cohen, Vice President

Jennifer McCahill, Treasurer

Dana L. Mark, Esq., Secretary

Tom Liebman, Director

Matthew Neal Miller, Director

Patricia Goldman

Carol J. Hamilton

Caroline Hirsch

Veronica Jordan, PhD

Edward Labaton, Esq.

Ylain G. Mayer

Chris Newcomb

John Orrico

Lisa Schreiber

Elle Simone Scott

Chris Tilberis

Robin Zarel

BOARD MEMBERS

Mona Baird

Susan D. Bazaar

Jeannette Chang

Carmel J. Cohen, MD

Mei-Li da Silva Vint, Esq.

Andrew Feuerstein, Esq.

Shelley Golden

NATIONAL LEADERSHIP COUNCIL

Judith Abrams

Terri McKnight, CPA

Diane Rader O'Connor

SCIENTIFIC ADVISORY COMMITTEE

Beth Karlan, MD, CHAIR (2019-present)
UCLA Medical Center, Los Angeles, CA

Ronald Alvarez, MD (2016-present)
Vanderbilt University Medical Center, Nashville, TN

Deborah Armstrong, MD (2016-present)
Johns Hopkins School of Medicine, Baltimore, MD

Robert C. Bast Jr., MD (1997-present)
MD Anderson Cancer Center, Houston, TX

Andrew Berchuck, MD, (2000-present)
Duke Comprehensive Cancer Center, Durham, NC

Jonathan S. Berek, MD, MMS (1997-present)
Stanford University School of Medicine, Palo Alto, CA

Molly Brewer, DVM, MD, MS (2004-present)
*University of Connecticut Health Center,
Farmington, CT*

Ronald Buckanovich, MD, PhD (2013-present)
Magee-Womens Research Institute, Pittsburgh, PA

Robert Coleman, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Alan D'Andrea, MD (2017-present)
Dana-Farber Cancer Institute, Boston, MA

Ronny I. Drapkin, MD, PhD (2011-present)
University of Pennsylvania, Philadelphia, PA

Annie Ellis (2016-present)
Patient Advocate

Ellen Goode, PhD (2019-present)
Mayo Clinic, Rochester, MN

Dineo Khabele, MD (2015-present)
Washington University School of Medicine, St. Louis, MO

Ernst Lengyel, MD, PhD (2013-present)
University of Chicago, Chicago, IL

Douglas Levine, MD (2010-present)
New York University Langone Health, New York, NY

Ursula Matulonis, MD (2014-present)
Dana-Farber Cancer Institute, Boston, MA

Kenneth Nephew, PhD (2014-present)
Indiana University Simon Cancer Center, Bloomington, IN

Celeste Leigh Pearce, PhD, MPH (2015-present)
University of Michigan, Ann Arbor, MI

Kunle Odunsi, MD, PhD (2014-present)
*Roswell Park Comprehensive Cancer Center,
Buffalo, NY*

Sandra Orsulic, PhD (2011-present)
UCLA David Geffen School of Medicine, Los Angeles, CA

Daniel Powell Jr., PhD (2015-present)
University of Pennsylvania, Philadelphia, PA

Stephen Rubin, MD (2000-present)
Fox Chase Cancer Center, Philadelphia, PA

Carolyn D. Runowicz, MD (1997-present)
Florida International University, Miami, FL

Ie-Ming Shih, MD, PhD (2013-present)
*Johns Hopkins University School of Medicine,
Baltimore, MD*

Anil Sood, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Shelley Tworoger, PhD (2019-present)
Moffit Cancer Center, Tampa, FL

STAFF

Audra Moran

President & CEO

Bibi Ali

Vice President, Finance

Leslie Almiron

Associate Director, Finance

Jorge Calderon

Associate, Finance

Jake Carlin

Manager, Development & Events

David Carroll

Manager, Database

Erin Cassin

Manager, Social Media & Content

Vanessa Cramer

Director, Policy

Sarah DeFeo

Vice President, Scientific Affairs

Candice Harrison

Associate Manager, Development & Events

Rohan Jyothinagaram

Assistant, Programs & Operations

Odia Kane

Kolker Fellow

Jason Lalonde

Manager, Development & Events

Deb Levy

Vice President, Marketing & Communications

Kim Liao

Associate, Development

Erin Merkl

Assistant, Operations

Chad Ramsey

Vice President, Policy

Nikki Wargo

Senior Director, Events & Corporate Partnerships

Lindsey Weeks

Director, Digital Communications

Jon Zeidman

Vice President, Development

(Staff listed are current as of 12/21/2020)

FINANCIAL STATEMENT

2019

Revenue

Revenue & Support \$7,418,256

Investment income, net \$3,331,069

Total Revenue, Support & Investments \$10,749,325

Expenses

Program Services

Research \$6,746,090

Conference \$633,745

Education, Support and Advocacy \$1,653,173

Total Program Services \$9,033,008

Fundraising \$1,212,262

Administrative \$940,941

Total Expenses \$11,186,211

Ending Net Assets \$18,999,892
